Clinical Trial

Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma

Study acronym: GEM-BELACOMBOS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demographics, disease characteristics and treatment history data) treated in first or second relapse with belantamab mafodotin combinations under compassionate use conditions.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-06-19
Trial Details
NCT Number NCT07637526
Lead Sponsor PETHEMA Foundation
Conditions Relapse Multiple Myeloma
Enrollment 100 participants
Start Date 2026-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-24